Dr Toh Han Chong is Deputy CEO, National Cancer Centre Singapore and Professor at Duke NUS Medical School. He obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. Dr Toh received the National Senior Clinician Scientist Award in 2017, National Medical Excellence Award (NMEA) in 2018 and the NMRC STaR Award in 2022. He is European Society for Medical Oncology (ESMO) Scientific Faculty for Cancer Immunology & Immunotherapy and chair of Investigational Immunotherapy at ESMO Annual Congress 2026 in Madrid, Spain. Dr Toh has published over 160 peer review journal papers.
